Qualitative research methods were used to explore factors that may affect medical information seeking, treatment engagement, and emotional adjustment among African American cancer patients. Focus group findings suggest that an array of cultural and socioeconomic factors plays important roles in the behavior of African American cancer patients. Participants described a number of important barriers and facilitators of medical information seeking and treatment participation. Factors linked to the health care-related behaviors and adjustment of African American cancer patients included limited knowledge and misinformation about cancer, mistrust of the medical community, concerns about privacy, lack of insurance, religious beliefs, and emotional issues such as fear and stigma associated with seeking emotional support. Recommendations are made that may assist mental and physical health providers in improving patient information and mental and physical health outcomes of African American cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10810730290088094 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sarcoidosis is a multisystem disease process with a bimodal distribution typically affecting African American women and those of Scandinavian descent characterized by noncaseating granulomatous disease. We present a case of a 29-year-old African American male patient who was seen in the clinic for recurrent symptomatic cholelithiasis. He had no past medical history or symptoms besides intermittent postprandial right upper quadrant (RUQ) pain with imaging confirming cholelithiasis.
View Article and Find Full Text PDFEvolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.
Cureus
December 2024
Pain Medicine, Fondazione Paolo Procacci, Rome, ITA.
Systemic lupus erythematosus (SLE) is an autoimmune disease that more commonly affects African American people, although it is seen in people of all racial backgrounds. This condition is characterized by a dysregulated immune response resulting in widespread inflammation. Clinical manifestations caused by this inflammation include arthritis, anemia, cutaneous rashes, pleuritis, and nephritis.
View Article and Find Full Text PDFGeneral social support is commonly studied as a psychosocial resource that improves African Americans' well-being; we know less about how varied indicators of social support influence African Americans' depressive symptoms. Further, it is unclear how social support affects depressive symptoms differently when considering the moderating role of education. Using the National Survey of American Life (NSAL) (n = 3,278), we examined (1) the association between educational attainment and depressive symptoms, (2) the association between social support and depressive symptoms, and (3) whether education moderates the social support-depressive symptoms relationship among African Americans.
View Article and Find Full Text PDFPolygenic risk for epigenetic aging and adverse life experiences interact to predict growth in adolescent depression in a racially/ethnically diverse sample.
Front Psychiatry
December 2024
Psychology Department, Arizona State University, Tempe, AZ, United States.
Introduction: Research has yet to examine the interplay between indices of environmental risk and resilience processes and genetic predisposition for epigenetic aging in predicting early adolescent depressive symptoms. In the current study we examine whether adverse life events and parental acceptance moderate polygenic predisposition for GrimAge epigenetic aging in predicting trajectories of depressive symptoms across early adolescence.
Method: Using data from the Adolescent Brain Development Study (ABCD, N = 11,875), we created polygenic scores for GrimAge, and examined whether exposure to adverse life events and parental acceptance moderated the relation between genetic risk and depressive symptom trajectories from age 10/11 to 12/13 using growth mixture modelling.
Background: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2). Here, we report results from cohort 1 of this clinical trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!